Reviewer’s report

Title: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

Version: 5 Date: 30 November 2010

Reviewer: David Wald

Reviewer’s report:

The authors have addressed all the major issues and no further major revisions are required.

One essential minor revision is needed to the Conclusion of the Abstract, which incorrectly states that "we failed to document the anticipated risk factor reductions with the Polypill". Risk factor reductions were documented on the Polypill but it was not possible to quantify these because the control group received similar treatment. I would suggest the following Conclusion in place of the existing one.

"We successfully completed a Polypill feasibility trial in Sri Lanka. We were able to document high acceptability of the Polypill to patients and physicians. We were unable to estimate the risk factor reductions on the Polypill because the control group received similar treatment with individual drugs. The Polypill was however simpler and achieved comparable risk factor reductions, highlighting its potential usefulness in the prevention of CVD"